Bar Harbor Wealth Management Has $62.86 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Bar Harbor Wealth Management reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 76,113 shares of the company's stock after selling 835 shares during the quarter. Eli Lilly and Company comprises 4.2% of Bar Harbor Wealth Management's investment portfolio, making the stock its 2nd largest position. Bar Harbor Wealth Management's holdings in Eli Lilly and Company were worth $62,862,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock valued at $57,320,226,000 after purchasing an additional 475,530 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after purchasing an additional 291,875 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $8,407,908,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.8%

Shares of LLY stock traded up $6.53 during mid-day trading on Friday, hitting $818.56. The company's stock had a trading volume of 2,753,537 shares, compared to its average volume of 3,651,762. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The business has a 50-day moving average price of $773.53 and a 200 day moving average price of $801.30. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $775.78 billion, a price-to-earnings ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LLY shares. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective for the company. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.